Cat.No. : VNV-101
Storage: -80°C Shipping: Dry ice
| Cat. No. | VNV-101 |
| Description | These viruses are wild type parainfluenza virus type 3 particles which are replication-competent. This product is intended for research use only. |
| Shipping | Dry ice |
| Storage | -80°C |
| Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots. | |
| Mycoplasma | Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination. |
| Purity | Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards. |
| Sterility | The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities. |
| Proviral Identity Confirmation | All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert. |
Human parainfluenza virus type 3 (HPIV3) can induce pneumonia and bronchiolitis in infants and children when it infects lower respiratory tract epithelial cells and may cause asthma attacks in children and adults. Here, researchers evaluated the effects of HPIV3 infection on cultured human nasal epithelial cells (HNEC) and their release of interferon-γ and other cytokines. HPIV3-infected HNEC did not induce cytotoxicity for at least 48 h, but interferon-γ (IFN-γ) protein concentrations in cell supernatants were significantly increased at 24 and 48 h after infection (by 387% and 485%, respectively, compared with mock-infected cells). IFNγ mRNA expression was significantly increased 24 h after infection. RANTES protein concentrations and mRNA expression were significantly increased 72 h after infection. No measurable concentrations of TNF-α, IL-10, TSLP, IL-8, GM-CSF, or eotaxin were detected in the supernatants of virus-infected cells. Thus, HPIV3 can efficiently infect upper airway epithelial cells, and infection is associated with the induction of IFN-γ and the production of RANTES.
In the supernatant of uninfected cells, IFN-γ protein was detectable at 24 h (mean concentration 3.2 ± 1.2 pg/mL), 48 h (mean concentration 2.8 ± 0.9 pg/mL), and 72 h (mean concentration 2.9 ± 1.9 pg/mL). After PIV3 infection, IFN-γ protein levels increased significantly at 24 h (mean concentration 387%) and 48 h (mean concentration 485%), but decreased significantly at 72 h (Figure 1A). Compared with mock-infected cells, IFN-γ protein concentrations at all three multiplicity of infection (MOI) levels increased significantly at 24 h (mean 10.2 ± 3.1 pg/mL for MOI 0.001, mean 12.4 ± 2.9 pg/mL for MOI 0.01, and mean 14.8 ± 2.3 pg/mL for MOI 0.1) (Figure 1B). After 24 hours of infection, the expression of IFN-γ mRNA increased significantly by 174% compared with the uninfected control group, and decreased by 28% and 66% at 48 hours and 72 hours after infection, respectively, compared with the control group (Figure 1C).
Figure 1. PIV-3 induced IFN-γ protein release and mRNA expression in RPMI 2650 cells. (Lewandowska-Polak A, et al., 2015)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Creative Biogene's Parainfluenza Type 3 is a high-quality product. We achieved excellent viral recovery in our animal challenge studies, and the growth curve in cell culture was textbook perfect.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
